PD-L1 has emerged as a potential biomarker for immunotherapy selection, as several PD-L1-targeted immunotherapeutics have only shown efficacy in select patient populations.22 Development of diagnostic agents are needed which can assess PD-L1 tumor and tumor microenvironment status. This evidence concerns the gene CD274 and neoplasm.